-
公开(公告)号：US11324818B2
公开(公告)日：2022-05-10
申请号：US16334683
申请日：2017-09-21
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Darren Hockman , Chao Chen
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
-
公开(公告)号：US20220105175A1
公开(公告)日：2022-04-07
申请号：US17511177
申请日：2021-10-26
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Darren Hockman , Chao Chen
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
-
公开(公告)号：US11186615B2
公开(公告)日：2021-11-30
申请号：US15763370
申请日：2016-10-07
发明人： Michael Houghton , Darren Hockman , John L. Law , Chao Chen , Michael Logan
IPC分类号： C07K14/005 , C12N15/62 , C12P21/02 , C07K1/22 , C07K19/00 , A61K39/12 , A61P31/14 , A61K39/29 , C12N7/00 , A61K39/00
摘要： The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.
-
公开(公告)号：US12048742B2
公开(公告)日：2024-07-30
申请号：US16978486
申请日：2019-03-14
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Chao Chen , Darren Hockman
CPC分类号： A61K39/29 , A61P31/14 , A61P37/04 , A61K2039/55505 , C12N2770/24222 , C12N2770/24234
摘要： The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.
-
公开(公告)号：US20190209677A1
公开(公告)日：2019-07-11
申请号：US16334683
申请日：2017-09-21
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Darren Hockman , Chao Chen
IPC分类号： A61K39/29
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/55544 , A61K2039/70 , C12N2710/10034 , C12N2710/10043 , C12N2710/24134 , C12N2710/24143 , C12N2770/24234
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
-
公开(公告)号：US20180282377A1
公开(公告)日：2018-10-04
申请号：US15763370
申请日：2016-10-07
发明人： Michael Houghton , Darren Hockman , John L. Law , Chao Chen , Michael Logan
IPC分类号： C07K14/005 , C12N7/00 , A61K39/29
摘要： The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.027 秒)
